Decision delayed over NH state Rx data

Share this article:
A federal judge took an unusual step last month of asking lawyers to critique a draft of his factual findings before ruling in IMS Health and Verispan’s high-profile challenge to New Hampshire’s state law limiting drug company access to doctors’ prescribing habits.

The Associated Press reported that Judge Paul Barbadoro asked lawyers for both sides in the case to meet with him to review his proposed factual findings, apparently in hopes to address some objections before ruling and providing the 1st US Circuit Court of Appeals in Boston with a clear decision.

Barbadoro cautioned that no one should try to predict his ruling from the draft, but some
of his comments showed his skepticism about key arguments—including the state’s contention that detailing drives up drug prices.

“If reasonable medical people disagree,” about the merits of various drugs for the same medical condition, “you have a stronger argument that speech restrictions are dangerous,” Barbadoro said. He expects to rule this month.  

Share this article:

Email Newsletters

More in News

FDA kind of OKs Lilly/BI's Lantus look-alike

FDA kind of OKs Lilly/BI's Lantus look-alike

Sanofi's patent lawsuit triggered the tentative approval of the Lilly-BI Lantus competitor.

GSK relaunches COPD.com

GSK relaunches COPD.com

The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.

Six things for pharma marketers to know: Tuesday, August 19

Six things for pharma marketers to know: Tuesday, ...

Lilly/BI receives tentative approval for insulin biosimilar; Ebola death rate hits new high; LaMattina sounds off on Pfizer's oncology efforts; art therapy becoming the norm in hospitals.